Could home sexually transmitted infection specimen collection with e-prescription be a cost-effective strategy for clinical trials and clinical care?

Diane R. Blake, Freya Spielberg, Vivian Levy, Shelly Lensing, Peter A. Wolff, Lalitha Venkatasubramanian, Nincoshka Acevedo, Nancy Padian, Ishita Chattopadhyay, Charlotte A Gaydos

Research output: Contribution to journalArticle

Abstract

Background: Results of a recent demonstration project evaluating feasibility, acceptability, and cost of a Web-based sexually transmitted infection (STI) testing and e-prescription treatment program (eSTI) suggest that this approach could be a feasible alternative to clinic-based testing and treatment, but the results need to be confirmed by a randomized comparative effectiveness trial. Methods: We modeled a decision tree comparing (1) cost of eSTI screening using a home collection kit and an e-prescription for uncomplicated treatment versus (2) hypothetical costs derived from the literature for referral to standard clinic-based STI screening and treatment. Primary outcome was number of STIs detected. Analyses were conducted from the clinical trial perspective and the health care system perspective. Results: The eSTI strategy detected 75 infections, and the clinic referral strategy detected 45 infections. Total cost of eSTI was $94,938 ($1266/ STI detected) from the clinical trial perspective and $96,088 ($1281/STI detected) from the health care system perspective. Total cost of clinic referralwas $87,367 ($1941/STI detected) fromthe clinical trial perspective and $71,668 ($1593/STI detected) from the health care system perspective. Conclusions: Results indicate that eSTI will likely be more cost-effective (lower cost/STI detected) than clinic-based STI screening, both in the context of clinical trials and in routine clinical care. Although our results are promising, they are based on a demonstration project and estimates from other small studies. A comparative effectiveness research trial is needed to determine actual cost and impact of the eSTI system on identification and treatment of new infections and prevention of their sequelae.

Original languageEnglish (US)
Pages (from-to)13-19
Number of pages7
JournalSexually Transmitted Diseases
Volume42
Issue number1
DOIs
StatePublished - Jan 20 2015

Fingerprint

Specimen Handling
Sexually Transmitted Diseases
Prescriptions
Clinical Trials
Costs and Cost Analysis
Delivery of Health Care
Referral and Consultation
Infection
Comparative Effectiveness Research
Decision Trees

ASJC Scopus subject areas

  • Dermatology
  • Public Health, Environmental and Occupational Health
  • Microbiology (medical)
  • Infectious Diseases

Cite this

Could home sexually transmitted infection specimen collection with e-prescription be a cost-effective strategy for clinical trials and clinical care? / Blake, Diane R.; Spielberg, Freya; Levy, Vivian; Lensing, Shelly; Wolff, Peter A.; Venkatasubramanian, Lalitha; Acevedo, Nincoshka; Padian, Nancy; Chattopadhyay, Ishita; Gaydos, Charlotte A.

In: Sexually Transmitted Diseases, Vol. 42, No. 1, 20.01.2015, p. 13-19.

Research output: Contribution to journalArticle

Blake, DR, Spielberg, F, Levy, V, Lensing, S, Wolff, PA, Venkatasubramanian, L, Acevedo, N, Padian, N, Chattopadhyay, I & Gaydos, CA 2015, 'Could home sexually transmitted infection specimen collection with e-prescription be a cost-effective strategy for clinical trials and clinical care?', Sexually Transmitted Diseases, vol. 42, no. 1, pp. 13-19. https://doi.org/10.1097/OLQ.0000000000000221
Blake, Diane R. ; Spielberg, Freya ; Levy, Vivian ; Lensing, Shelly ; Wolff, Peter A. ; Venkatasubramanian, Lalitha ; Acevedo, Nincoshka ; Padian, Nancy ; Chattopadhyay, Ishita ; Gaydos, Charlotte A. / Could home sexually transmitted infection specimen collection with e-prescription be a cost-effective strategy for clinical trials and clinical care?. In: Sexually Transmitted Diseases. 2015 ; Vol. 42, No. 1. pp. 13-19.
@article{1cc898cebd0c42dbb356333ab86e8235,
title = "Could home sexually transmitted infection specimen collection with e-prescription be a cost-effective strategy for clinical trials and clinical care?",
abstract = "Background: Results of a recent demonstration project evaluating feasibility, acceptability, and cost of a Web-based sexually transmitted infection (STI) testing and e-prescription treatment program (eSTI) suggest that this approach could be a feasible alternative to clinic-based testing and treatment, but the results need to be confirmed by a randomized comparative effectiveness trial. Methods: We modeled a decision tree comparing (1) cost of eSTI screening using a home collection kit and an e-prescription for uncomplicated treatment versus (2) hypothetical costs derived from the literature for referral to standard clinic-based STI screening and treatment. Primary outcome was number of STIs detected. Analyses were conducted from the clinical trial perspective and the health care system perspective. Results: The eSTI strategy detected 75 infections, and the clinic referral strategy detected 45 infections. Total cost of eSTI was $94,938 ($1266/ STI detected) from the clinical trial perspective and $96,088 ($1281/STI detected) from the health care system perspective. Total cost of clinic referralwas $87,367 ($1941/STI detected) fromthe clinical trial perspective and $71,668 ($1593/STI detected) from the health care system perspective. Conclusions: Results indicate that eSTI will likely be more cost-effective (lower cost/STI detected) than clinic-based STI screening, both in the context of clinical trials and in routine clinical care. Although our results are promising, they are based on a demonstration project and estimates from other small studies. A comparative effectiveness research trial is needed to determine actual cost and impact of the eSTI system on identification and treatment of new infections and prevention of their sequelae.",
author = "Blake, {Diane R.} and Freya Spielberg and Vivian Levy and Shelly Lensing and Wolff, {Peter A.} and Lalitha Venkatasubramanian and Nincoshka Acevedo and Nancy Padian and Ishita Chattopadhyay and Gaydos, {Charlotte A}",
year = "2015",
month = "1",
day = "20",
doi = "10.1097/OLQ.0000000000000221",
language = "English (US)",
volume = "42",
pages = "13--19",
journal = "Sexually Transmitted Diseases",
issn = "0148-5717",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Could home sexually transmitted infection specimen collection with e-prescription be a cost-effective strategy for clinical trials and clinical care?

AU - Blake, Diane R.

AU - Spielberg, Freya

AU - Levy, Vivian

AU - Lensing, Shelly

AU - Wolff, Peter A.

AU - Venkatasubramanian, Lalitha

AU - Acevedo, Nincoshka

AU - Padian, Nancy

AU - Chattopadhyay, Ishita

AU - Gaydos, Charlotte A

PY - 2015/1/20

Y1 - 2015/1/20

N2 - Background: Results of a recent demonstration project evaluating feasibility, acceptability, and cost of a Web-based sexually transmitted infection (STI) testing and e-prescription treatment program (eSTI) suggest that this approach could be a feasible alternative to clinic-based testing and treatment, but the results need to be confirmed by a randomized comparative effectiveness trial. Methods: We modeled a decision tree comparing (1) cost of eSTI screening using a home collection kit and an e-prescription for uncomplicated treatment versus (2) hypothetical costs derived from the literature for referral to standard clinic-based STI screening and treatment. Primary outcome was number of STIs detected. Analyses were conducted from the clinical trial perspective and the health care system perspective. Results: The eSTI strategy detected 75 infections, and the clinic referral strategy detected 45 infections. Total cost of eSTI was $94,938 ($1266/ STI detected) from the clinical trial perspective and $96,088 ($1281/STI detected) from the health care system perspective. Total cost of clinic referralwas $87,367 ($1941/STI detected) fromthe clinical trial perspective and $71,668 ($1593/STI detected) from the health care system perspective. Conclusions: Results indicate that eSTI will likely be more cost-effective (lower cost/STI detected) than clinic-based STI screening, both in the context of clinical trials and in routine clinical care. Although our results are promising, they are based on a demonstration project and estimates from other small studies. A comparative effectiveness research trial is needed to determine actual cost and impact of the eSTI system on identification and treatment of new infections and prevention of their sequelae.

AB - Background: Results of a recent demonstration project evaluating feasibility, acceptability, and cost of a Web-based sexually transmitted infection (STI) testing and e-prescription treatment program (eSTI) suggest that this approach could be a feasible alternative to clinic-based testing and treatment, but the results need to be confirmed by a randomized comparative effectiveness trial. Methods: We modeled a decision tree comparing (1) cost of eSTI screening using a home collection kit and an e-prescription for uncomplicated treatment versus (2) hypothetical costs derived from the literature for referral to standard clinic-based STI screening and treatment. Primary outcome was number of STIs detected. Analyses were conducted from the clinical trial perspective and the health care system perspective. Results: The eSTI strategy detected 75 infections, and the clinic referral strategy detected 45 infections. Total cost of eSTI was $94,938 ($1266/ STI detected) from the clinical trial perspective and $96,088 ($1281/STI detected) from the health care system perspective. Total cost of clinic referralwas $87,367 ($1941/STI detected) fromthe clinical trial perspective and $71,668 ($1593/STI detected) from the health care system perspective. Conclusions: Results indicate that eSTI will likely be more cost-effective (lower cost/STI detected) than clinic-based STI screening, both in the context of clinical trials and in routine clinical care. Although our results are promising, they are based on a demonstration project and estimates from other small studies. A comparative effectiveness research trial is needed to determine actual cost and impact of the eSTI system on identification and treatment of new infections and prevention of their sequelae.

UR - http://www.scopus.com/inward/record.url?scp=84919346808&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84919346808&partnerID=8YFLogxK

U2 - 10.1097/OLQ.0000000000000221

DO - 10.1097/OLQ.0000000000000221

M3 - Article

C2 - 25504295

AN - SCOPUS:84919346808

VL - 42

SP - 13

EP - 19

JO - Sexually Transmitted Diseases

JF - Sexually Transmitted Diseases

SN - 0148-5717

IS - 1

ER -